Major Program
Phase 0 I II Cancer Prevention Clinical Trials Program
Research Group
Chemopreventive Agent Development
Sponsor
National Cancer Institute (NCI)
Status
Completed
ClinicalTrials.gov ID
For more information, see ClinicalTrials.gov NCT01497431
This randomized phase I trial studies the side effects and the best dose of Se-methyl-seleno-L-cysteine or selenomethionine in preventing prostate cancer in healthy participants. Chemoprevention is the use of certain drugs to keep cancer from forming. The use of Se-methyl-seleno-L-cysteine or selenomethionine, two different types of selenium compounds, may prevent prostate cancer from forming.
Intervention
Laboratory Biomarker Analysis, Methylselenocysteine, Pharmacological Study, Placebo, Selenium
Condition
No Evidence of Disease, Prostate Carcinoma
Investigators
Raymond Bergan